EPO和EPOR在肝细胞癌中的表达及临床意义

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (5): 397-402.

EPO和EPOR在肝细胞癌中的表达及临床意义

1 455000 河南安阳安阳市肿瘤医院内科 2 510060 中山大学肿瘤防治中心肝胆科

收稿日期:2017-11-22 修回日期:2018-02-28 出版日期:2018-05-31 发布日期:2018-06-07

The expression of EPO and EPOR in hepatocellular carcinoma and their clinical significance

Department of Internal Medicine， Tumor Hospital of Anyang， Anyang 455000， China

Received:2017-11-22 Revised:2018-02-28 Online:2018-05-31 Published:2018-06-07

摘要/Abstract

摘要： 目的检测促红细胞生成素（EPO）和促红细胞生成素受体（EPOR）在肝细胞癌（HCC）中的表达情况，并分析二者预测HCC预后的意义。方法采用免疫组化法检测EPO和EPOR在96例HCC组织和11例正常肝脏组织中的表达，分析EPO和EPOR在HCC中表达的相关性，及其与HCC临床病理特征及预后的关系。结果 HCC组织中EPO和EPOR高表达率分别为49.0％、46.9％，明显高于其在正常肝脏组织中的表达（0、0）。HCC组织中EPO与EPOR的表达呈正相关（r=0.207，P＜0.05）。EPO和EPOR表达均与Edmondson-Steiner病理分级密切相关（P＜0.05）。EPOR低表达组的1、3、5年无瘤生存率分别为76.2％、42.1％及16.5％，高表达组分别为55.6％、14.0％及7.8％，差异有统计学意义（P＜0.05）。EPOR低表达组的1、3、5年生存率分别为88.0％、76.0％及46.1％，高表达组分别为80.0％、43.6％及26.8％，差异有统计学意义（P＜0.05）。Cox多因素分析显示，卫星结节、EPOR表达是影响HCC患者术后无瘤生存的独立预后因素；卫星结节、血管侵犯和EPOR表达是影响HCC患者术后总生存的独立预后因素。结论 EPOR表达与HCC患者术后无瘤生存和总生存相关，可能是影响HCC预后的分子标志物。

关键词: 肝细胞癌, 促红细胞生成素, 促红细胞生成素受体

Abstract:

Objective To detect the expression of erythropoietin （EPO） and erythropoietin receptor （EPOR） in hepatocellular carcinoma （HCC） tissues and analyze their predictive value on the prognosis of HCC patients. Methods Immunohistochemistry technique was used to detect the expression of EPO and EPOR in 96 cases of HCC tissues and 11 cases of normal liver tissues. The difference of the expression of the two proteins in two tissues and the correlation of the expression of the two proteins were analyzed. Also， the relationship of the two proteins with clinicopathological features and prognosis of HCC patients were analyzed. Results The high expression rates of EPO and EPOR were 49.0％and 46.9％ in 96 cases of HCC tissues， higher than 0 and 0 in normal liver tissues. The expression of EPO was positively associated with that of EPOR（r=0.207， P＜0.05）. The expression of both EPO and EPOR was associated with Edmondson-Steiner histological grade（P＜0.05）. The 1-，3- and 5-year disease free survival rates were 76.2％，42.1％ and 16.5％ in low EPOR expression group， significantly higher than 55.6％， 14.0％ and 7.8％ in high EPOR expression group （P＜0.05）. Similarly， the 1-，3- and 5-year overall survival rates in low EPOR expression group were 88.0％， 76.0％ and 46.1％， significantly higher than 80.0％， 43.6％ and 26.8％ in high EPOR expression group（P＜0.05）. Multivariate analysis revealed that satellite nodules， the expression of EPOR were independent risk factors of disease free survival（P＜0.05）， and satellite nodules， vascular invasion and the expression of EPOR were independent risk factors of overall survival（P＜0.05）. Conclusion The expression of EPOR is correlated with disease free survival and overall survival of HCC patients， and maybe a prognosis biomarker of HCC.

Key words: Hepatocellular carcinoma（HCC）, Erythropoietin（EPO）, Erythropoietin receptor （EPOR）

中图分类号:

R735.7

梁文昌, 郭荣平, 王俊生, 周静.

EPO和EPOR在肝细胞癌中的表达及临床意义 [J]. 临床肿瘤学杂志, 2018, 23(5): 397-402.

LIANG Wenchang, GUO Rongping, WANG Junsheng, ZHOU Jing.. The expression of EPO and EPOR in hepatocellular carcinoma and their clinical significance [J]. Chinese Clinical Oncology, 2018, 23(5): 397-402.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	刘锦；李贵新；马传香. 恶性黑色素瘤腹腔转移１例[J]. 临床肿瘤学杂志, 2009, 14(1): 96 .
[2]	石　玮¹，华海清²，王兴华¹. 放疗对肠屏障功能的影响及研究进展[J]. 临床肿瘤学杂志, 2009, 14(1): 89 .
[3]	王杰军，李　睿. ＮＣＣＮ成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[4]	崔传亮，迟志宏，袁香庆，斯　璐，盛锡楠，郭　军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[5]	高亚杰¹，关小倩¹，杨海林¹，张　阳²，欧阳学农³，杨建伟⁴，陈　焰⁵,徐建明⁶，赵宣良⁷，王宝成⁸，刘文超⁹，张贺龙¹⁰，南克俊¹¹，王湘辉¹² . 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[6]	徐卫国¹，杨小青²，郝世柱¹，宋纪宁¹，张鹏东¹，胡潺潺¹，王文雅¹. 大肠癌组织中Ｎｅｕｒｏｐｉｌｉｎ-１的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[7]	许景艳¹，欧阳建^１，章宜芬²，周荣富¹，陈　兵¹，张启国¹，杨永公¹，邵小雁¹，徐　勇¹，关朝阳¹. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[8]	徐晓明¹，唐金海¹，刘万花²，郑凯尔²，秦建伟¹，赵祥生¹，张　彤³. 触诊阴性乳腺癌的定位方法与同期手术治疗[J]. 临床肿瘤学杂志, 2009, 14(1): 43 .
[9]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .
[10]	翟云芝¹，陈振东²，秦凤展¹. Ｅｚｒｉｎ和ＡＫＴ２在大肠癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(1): 25 .